Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Terbutaline Sulphate M3 vs M2 Turbuhaler
NCT02178059Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of terbutaline in asthma and bronchospasm (2 arms), sponsored by AstraZeneca. Primary endpoints: Area Under the Plasma Concentration-time Curve From Zero to the Time of Last Measurable Concentration at 36 hours and Maximum Observed Plasma Concentration at 36 hours. Started Aug 2014; status: completed.
02
Drugs
terbutaline
03
Conditions
asthmabronchospasm
Beyond the preview
Go deeper on NCT02178059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02178059.